Multiple sclerosis (MS) is a chronic inflammatory disease affecting the central nervous system. MS is the commonest cause of disability in young adults in the UK. Sheffield is a major UK trials centre for new drugs that have revolutionised MS therapy and are leaders in the UK for autologous haematopoietic stem-cell transplantation (AHSCT) in MS.
In the short term, we aim to establish standardised ways to to collect information about patient’s symptoms, and samples that can tell us about the underlying disease processes will help towards developing treatments that are more individually tailored in the future.
In the longer term, we aim to develop the Sheffield Bone Marrow Transplantation Programme into a centre of excellence for autologous haematopoietic stem cell transplantation (AHSCT); a new way to treat neuroinflammatory conditions like MS. Find out more about this treatment on the Sheffield Teaching Hospitals NHS Foundation Trust AHSCT website.